Please assess the completion status of the following clinical trial:

Trial Title: Multiple Islet Peptide Administration in Type 1 Diabetes (MultiPepT1De)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Type 1 diabetes~* Age 18-45 years~* Maximum of 4 years from diagnosis~* Evidence of ≥1 autoantibody against β-cell autoantigens~* Possession of the HLA-DR4 (DRB1\*0401) genotype~* Residual β-cell function (peak C-peptide \>200)~Exclusion Criteria:~* Females who are pregnant, breast-feeding or not using adequate forms of contraception.~* Use of β-cell stimulants, immunosuppressive or immunomodulatory therapies, including systemic steroids within 1 month prior to randomization, any monoclonal antibody therapy given for any indication and any antigen-specific

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Placebo injection (Type: PLACEBO_COMPARATOR): Water for injection
- MultiPepT1De injection low dose (Type: EXPERIMENTAL): Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)
- MultiPepT1De injection medium dose (Type: EXPERIMENTAL): Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)
- MultiPepT1De injection high dose (Type: EXPERIMENTAL): Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)

Based on this trial design, predict the completion outcome and termination type (if applicable).